What Is Denali Therapeutics Inc. (DNLI) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Denali Therapeutics Inc.'s intrinsic value is estimated at $9.26, suggesting the stock is overvalued at its current price of $22.65. With 11 out of 12 models flagging downside (-59.1% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +17.8% (fair value: $26.67), while ML-RIV is the most conservative at -96.8% ($0.73). The spread between these extremes — +114.5% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About DNLI?
12 of 13 models are currently active for DNLI. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates DNLI's intrinsic value at $7.03, implying -69.0% downside from the current price. See which stocks rank higher →
How Does DNLI Rank in Biological Products, (No Diagnostic Substances)?
Among 145 Biological Products, (No Diagnostic Substances) stocks, DNLI ranks #13 by Quality of Company score. CirclFi's QOC score of 7.3/10 evaluates 32 fundamental signals. A score of 7.3 indicates above-average quality.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Denali Therapeutics Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is DNLI a Value Trap?
The Value Trap algorithm is not active for DNLI. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Denali Therapeutics Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Denali Therapeutics Inc.'s fundamental quality profile registers 7.3/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +114.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every DNLI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across DNLI's 12 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad